口服镁补充剂对接受胰岛素治疗的2型糖尿病且血清镁偏低者的胰岛素敏感性无影响:一项随机对照试验
本研究采用随机、双盲、安慰剂对照交叉设计,比较口服镁补充剂(15 mmol/天)6周与安慰剂对接受胰岛素治疗的2型糖尿病且血清镁≤0.79 mmol/l患者的影响。共纳入14例受试者,主要终点为高胰岛素-正常血糖钳夹试验最后30分钟的平均葡萄糖输注率(M值)。结果显示镁补充剂虽使血清镁和尿镁排泄增加,但M值、血糖控制、胰岛素剂量、血脂和血压与安慰剂无显著差异,仅HDL-胆固醇在镁剂后较低。
要点
- 口服镁补充剂15 mmol/天持续6周,未改善胰岛素敏感性(M值4.6±0.5 vs 4.4±0.6 mg kg-1 min-1,p=0.108)。
- 镁剂使血清镁(0.75±0.02 vs 0.70±0.02 mmol/l,p=0.016)和尿镁排泄增加。
- 镁剂后HDL-胆固醇较低(1.14±0.08 vs 1.20±0.09 mmol/l,p=0.026),其余血脂、血压、血糖控制无差异。
核心结论
- 尽管血清镁浓度有轻度升高,口服镁补充剂未改善接受胰岛素治疗的2型糖尿病且血清镁偏低者的胰岛素敏感性。
研究设计与样本
- 随机、双盲(参与者和研究者均对治疗顺序设盲)、安慰剂对照交叉研究,比较口服镁补充剂(15 mmol/天)6周与匹配安慰剂。
- 纳入接受胰岛素治疗的2型糖尿病患者(年龄≥18岁,BMI 18-40 kg/m2,HbA1c <100 mmol/mol [11.3%],血清镁≤0.79 mmol/l),从门诊和广告招募。
- 采用区组随机化,两种治疗顺序在试验人群中均匀分布;共招募14例参与者(50%女性,100%白人,平均±SD年龄67±6岁,BMI 31±5 kg/m2,HbA1c 58±9 mmol/mol [7.4±0.9%])。
- 主要结局为高胰岛素-正常血糖钳夹试验最后30分钟的平均葡萄糖输注率(即M值)。
主要发现
- 镁补充剂组血清镁水平较安慰剂组升高(0.75±0.02 vs 0.70±0.02 mmol/l,p=0.016),尿镁排泄(镁/肌酐比值)也升高(0.23±0.02 vs 0.15±0.02,p=0.005)。
- 葡萄糖钳夹M值在镁组与安慰剂组间无差异(4.6±0.5 vs 4.4±0.6 mg kg-1 min-1,p=0.108)。
- 6周治疗期间,连续葡萄糖监测指标、HbA1c、胰岛素剂量、血脂谱和血压均无差异,但镁组HDL-胆固醇浓度低于安慰剂组(1.14±0.08 vs 1.20±0.09 mmol/l,p=0.026)。
- 可能与低镁血症相关的症状在两组治疗臂相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Hypomagnesaemia has been associated with insulin resistance and an increased risk of type 2 diabetes. Whether magnesium supplementation improves insulin sensitivity in people with type 2 diabetes and a low serum magnesium level is unknown. METHODS: Using a randomised, double-blind (both participants and investigators were blinded to the participants' treatment sequences), placebo-controlled, crossover study design, we compared the effect of oral magnesium supplementation (15 mmol/day) for 6 weeks with that of matched placebo in individuals with insulin-treated type 2 diabetes (age ≥18 years, BMI 18-40 kg/m2, HbA1c <100 mmol/mol [11.3%], serum magnesium ≤0.79 mmol/l). Participants were recruited from the outpatient clinic and through advertisements. Randomisation to a treatment sequence order was done using a randomisation list. We used block randomisation and the two possible treatment sequences were evenly distributed among the trial population. The primary outcome was the mean glucose infusion rate during the final 30 min of a hyperinsulinaemic-euglycaemic clamp (i.e. M value). Secondary outcomes included variables of glucose control, insulin need, BP, lipid profile and hypomagnesaemia-related symptoms during follow-up. RESULTS: We recruited 14 participants (50% women, 100% White, mean ± SD age 67±6 years, BMI 31±5 kg/m2, HbA1c 58±9 mmol/mol [7.4±0.9%]) with insulin-treated type 2 diabetes. Magnesium supplementation increased both mean ± SEM serum magnesium level (0.75±0.02 vs 0.70±0.02 mmol/l, p=0.016) and urinary magnesium excretion (magnesium/creatinine ratio, 0.23±0.02 vs 0.15±0.02, p=0.005), as compared with placebo. The M value of the glucose clamp did not differ between the magnesium and placebo study arms (4.6±0.5 vs 4.4±0.6 mg kg-1 min-1, p=0.108). During the 6 weeks of treatment, continuous glucose monitoring outcomes, HbA1c, insulin dose, lipid profile and BP also did not differ, except for a lower HDL-cholesterol concentration after magnesium compared with placebo (1.14±0.08 vs 1.20±0.09 mmol/l, p=0.026). Symptoms potentially related to hypomagnesaemia were similar for both treatment arms. CONCLUSIONS/INTERPRETATION: Despite an albeit modest increase in serum magnesium concentration, oral magnesium supplementation does not improve insulin sensitivity in people with insulin-treated type 2 diabetes and low magnesium levels. TRIAL REGISTRATION: EudraCT number 2021-001243-27. FUNDING: This study was supported by a grant from the Dutch Diabetes Research Foundation (2017-81-014).
引用
- Drenthen LCA, de Baaij JHF, Rodwell L, et al. Oral magnesium supplementation does not affect insulin sensitivity in people with insulin-treated type 2 diabetes and a low serum magnesium: a randomised controlled trial. Diabetologia. 2023. PMID: 37922013. doi:10.1007/s00125-023-06029-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。